Background {#Sec1}
==========

Nosocomial bloodstream infections (NBSIs) are one of the most severe types of healthcare-associated infections (HAIs), are a major cause of mortality, and are associated with significantly prolonged length of stay (LOS) in hospital and increased healthcare costs \[[@CR1]--[@CR3]\], especially in intensive care units (ICUs) \[[@CR4]\]. NBSIs are consisted of central line-associated bloodstream infections (CLABSIs) and non-central line-associated bloodstream infections (N-CLABSIs) according to the American Centers for Disease Control and Prevention (CDC)-National Healthcare Safety Network (NHSN) \[[@CR5]\]. Most of the previous studies focused on CLABSIs, which have clear preventability. Several evidence-based guidelines have been developed to prevent and reduce CLABSIs \[[@CR6], [@CR7]\]. A 46% reduction in CLABSIs has been obtained in hospitals across the USA from 2008 to 2013 \[[@CR8]\].

By contrast, N-CLABSI is a forgotten issue that has been poorly studied, especially in the Chinese population. N-CLABSI may be more common in NBSIs along with the reduction of CLABSI. It is still uncertain about whether patients with N-CLABSI have poorer outcomes than those without N-CLABSI or with CLABSI and whether N-CLABSI could be prevented. This study was performed to investigate the clinical impacts and risk factors for N-CLABSI in ICU patients to identify risk factors that could be controlled.

Methods {#Sec2}
=======

Study design and settings {#Sec3}
-------------------------

This observational study was conducted using electronic medical record (EMR) data in a general ICU of West China Hospital, Sichuan University, southwestern China. It is a 50-bed ICU for adult patients that receives approximately 1300 admissions per year, in a 5000-bed tertiary-care hospital. It is the major referral center in western China for patients with a variety of critical conditions such as severe acute pancreatitis, malignancy, liver transplantation, multiple organ failure, and severe pneumonia.

Study population {#Sec4}
----------------

All patients aged ≥ 18 years admitted to the ICU \> 2 days from January 2013 to December 2017 were eligible for inclusion in this study. Those with long ICU stay because of medical disputes or with both N-CLABSI and CLABSI during the same ICU stay were excluded. The exposed group in the cohort for the outcomes was consisted of all the patients with ICU-acquired N-CLABSI, while the control group consisted of all the patients without ICU-acquired N-CLABSI (including those with CLABSI).

Definitions {#Sec5}
-----------

N-CLABSIs in this study were consisted of primary and secondary BSIs defined by the American CDC-NHSN \[[@CR5]\]. A N-CLABSI developed 2 days after admission to the ICU and within 2 days of discharge from the ICU was defined as an ICU-acquired N-CLABSI. BSI date was defined as the date of the positive blood sampling. A BSI that occurred after the NHSN 14-day repeat infection timeframe of the previous BSI was defined as a new BSI. For the analysis of clinical impacts, the confounders were considered during the whole stay in ICU. For the analysis of risk factors, possible factors were considered prior to the N-CLABSI date in patients with N-CLABSI, while those were considered during the whole stay in ICU in patients without N-CLABSI. For patients with 2 or more N-CLABSI episodes, possible factors were analyzed prior to the first N-CLABSI episode.

Outcomes {#Sec6}
--------

The outcomes in this study were consisted of LOS in ICU, LOS in hospital, hospitalization costs, death in ICU (all-cause mortality), and predicted death in ICU. Predicted death in ICU included death in ICU and discharging from ICU against medical advice because of critical conditions and the desire to pass away at home.

Data source {#Sec7}
-----------

All patient data were retrieved from the medical record database of the EMR system, which was established in 2009, with annual discharged patients exceeding 200,000. Prospective surveillance of HAIs was performed by infection control practitioners and ICU nurses, using the HAI definitions updated annually by the American CDC-NHSN \[[@CR5]\]. This study was approved (No. WCH2018-409) by the Ethics Committee of West China Hospital, Sichuan University, with the waiver of informed consents. Patient data were anonymized prior to analysis.

Data collection {#Sec8}
---------------

Patient data included demographic characteristics (age, sex), illness severity, comorbidities on ICU admission, invasive procedures, multidrug-resistant organisms (MDROs), HAIs, and outcomes. Illness severity was evaluated by Acute Physiology and Chronic Health Evaluation (APACHE) II score \[[@CR9]\] during the first 24 h on ICU admission. Comorbidities on ICU admission including chronic underlying diseases (diabetes, hypertension, respiratory diseases, cardiovascular diseases, renal diseases, liver diseases, and malignancies), disorder of consciousness, gastrointestinal bleeding, trauma, immunological diseases, organ transplantation, multiple organ failure, shock, pancreatitis, acute respiratory distress syndrome (ARDS), and sepsis were retrieved from the diagnoses on ICU admission. Invasive procedures included surgical operation, intravascular catheters, organ biopsy, mechanical ventilation (MV), and urinary catheters (UC). All invasive procedures were conducted after hospital admission according to the medical orders in the EMR system, except surgical operation. Surgical operation and MDROs were considered from 1 year prior to this ICU admission. HAIs including BSI were retrieved from HAI surveillance. Pneumonia in the comorbidities on ICU admission and in HAIs was combined for analyzing, as well as intraabdominal infection (IAI). The outcomes were retrieved or evaluated from the medical records (predicted deaths were evaluated from the discharge records of EMR).

Statistical analysis and bias control {#Sec9}
-------------------------------------

Statistical analysis was performed using the SPSS program (version 19.0; SPSS, Chicago, IL, USA) and the STATA software (version 15.0; StataCorp LLC, USA). Continuous numerical variables were described as means and standard deviations (SD) when fitting a normal distribution, otherwise as medians and interquartile ranges. The independent sample *T* test was used to determine the differences in means after the homogeneity test of variances, while the Wilcoxon signed rank tests for median values. Categorical data were analyzed by the chi-square test or continuous correction chi-square test. Propensity score (PS) matching was used to ensure that both the two groups had similar baseline characteristics in the cohorts of the outcomes, which was estimated applying multivariable logistic regression models. A standardized difference ≤ 0.1 for a baseline covariate reveals a negligible imbalance \[[@CR10]\]. The clinical impacts were analyzed by the new cohorts after PS matching, by multiple linear regression models (non-normally distributed outcomes were conducted by logarithmic transformations) or logistic regression models. To ensure the parsimony of the final multivariate regression models for the outcomes and N-CLABSI, variables for inclusion were carefully chosen, given the number of cases available. The variables with a *p* value \< 0.1 in the univariate analysis and those that were considered clinically relevant according to the advices of clinical experts and previous studies were selected into the multivariate regression models. Multicollinearity was analyzed for all the independent variables in the final models. The interaction between the factors was investigated. All tests were two-sided, and *p* \<  0.05 was considered statistically significant.

Results {#Sec10}
=======

Epidemiology of N-CLABSI in ICU patients {#Sec11}
----------------------------------------

A total of 6627 patients with 87,984 patient-days (13.3 days for the average LOS in ICU) were admitted to the ICU during this 5-year period. As shown in Fig. [1](#Fig1){ref-type="fig"}, 1,418 patients with LOS in ICU ≤ 2 days, 142 aged \< 18 years, 10 with long ICU stay because of medical disputes, and 11 with both N-CLABSI and CLABSI during the same ICU stay were excluded. After the exclusion of non-eligible patients, 5046 patients with 80,905 patient-days were included in this study, of which 155 (3.1 cases per 100 patients, 1.9 cases per 1000 patient-days) developed 168 ICU-acquired N-CLABSI episodes (2.1 episodes per 1000 patient-days) in the ICU (Fig. [1](#Fig1){ref-type="fig"}). Patients with N-CLABSI had a much higher proportion (71.8%) in the patients with NBSI than those with CLABSI (61 cases, 28.2%). The proportion of N-CLABSI increased from 70.2% in 2013 to 78.3% in 2017 (Fig. [2](#Fig2){ref-type="fig"}).Fig. 1Inclusion and exclusion of patients in this study. ICU, intensive care unit; N-CLABSI, non-central line-associated bloodstream infection; CLABSI, central line-associated bloodstream infectionFig. 2Proportion of N-CLABSI in NBSIs yearly. N-CLABSI, non-central line-associated bloodstream infection; NBSIs, nosocomial bloodstream infections

The 155 patients with N-CLABSI were 20 to 97 years old (mean, 53.3 years old), were mostly male (110, 71.0%), and had a mean APACHE II score on ICU admission of 21.0. N-CLABSI developed 3--116 days after admission to ICU (median, 13 days). Most N-CLABSIs (*n* = 135, 87.1%) were secondary BSIs, while the remaining 20 (12.9%) were primary BSIs. There were 203 bacterial or fungal strains recovered from the 168 N-CLABSI episodes. *Acinetobacter baumannii* (53 isolates, 26.1%) was the most common followed by *Klebsiella pneumoniae* (41 isolates, 20.2%) (Fig. [3](#Fig3){ref-type="fig"}).Fig. 3Frequency of isolates of N-CLABSI pathogens. N-CLABSI, non-central line-associated bloodstream infection; KP, *Klebsiella pneumoniae*; MRSA, methicillin-resistant *Staphylococcus aureus*

Comparisons of patients with N-CLABSI versus without N-CLABSI or with CLABSI {#Sec12}
----------------------------------------------------------------------------

Baseline demographic and clinical features of all 5046 eligible patients included in this study and results of comparisons of patients with N-CLABSI versus those without N-CLABSI or with CLABSI are shown in Table [1](#Tab1){ref-type="table"}. Patients with N-CLABSI have significantly longer LOS in ICU (median, 32 vs 10 days, by 22 days, *p* \<  0.001), longer LOS in hospital (median, 42 vs 21 days, by 21 days, *p* \<  0.001), higher hospitalization costs (median, 305,074 vs 97,591 yuan \[difference 207,483-yuan, equivalent to USD 30,738\], *p* \<  0.001), increased mortality in ICU (25.2% vs 13.0%, by 12.2%, *p* \<  0.001), and increased predicted mortality in ICU (58.1% vs 27.5%, by 20.6%, *p* \<  0.001) than those without N-CLABSI. Interestingly, there were no significant differences in all the outcomes (additionally including LOS in ICU or hospital after NBSI date) between the patients with N-CLABSI and those with CLABSI (*p* \> 0.05).Table 1Baseline clinical features and outcomes of patients with N-CLABSI or without N-CLABSIFeaturesPatients with N-CLABSI (*n* = 155) (group A)Patients without N-CLABSI\
(*n* = 4891) (group B\*)Patients with CLABSI\
(*n* = 64) (group B-sub)*p* value^†^A vs. BA vs. B-subAge (years), mean ± SD53.3 ± 16.456.9 ± 17.758.4 ± 16.0*0.0120.039*Sex, no. male (%)110 (71.0)3174 (64.9)43 (70.5)0.1180.945APACHE II score on ICU admission, mean ± SD21.0 ± 8.019.0 ± 8.122.4 ± 8.5*0.002*0.272Chronic underlying diseases, no. (%)107 (69.0)3342 (68.3)51 (83.6)0.853*0.030* Diabetes, no. (%)30 (19.4)619 (12.7)18 (29.5) Hypertension, no. (%)35 (22.6)1028 (21.0)21 (34.4) Respiratory diseases, no. (%)16 (10.3)654 (13.4)7 (11.5) Cardiovascular diseases, no. (%)27 (17.4)744 (15.2)15 (24.6) Renal diseases, no. (%)23 (14.8)609 (12.5)12 (19.7) Liver diseases, no. (%)52 (33.5)1147 (23.5)26 (42.6) Malignancies, no. (%)18 (11.6)1138 (23.3)10 (16.4)Disorder of consciousness, no. (%)21 (13.5)479 (9.8)10 (16.4)0.1230.591Gastrointestinal bleeding, no. (%)25 (16.1)395 (8.1)9 (14.8)*\< 0.001*0.803Trauma, no. (%)30 (19.4)720 (14.7)6 (9.8)0.1100.091Immunological diseases, no. (%)18 (11.6)767 (15.7)11 (18.0)0.1690.213Organ transplantation, no. (%)15 (9.7)536 (11.0)8 (13.1)0.6150.461Multiple organ failure, no. (%)62 (40.0)1150 (23.5)24 (39.3)*\< 0.001*0.929Shock, no. (%)69 (44.5)1118 (22.9)25 (41.0)*\< 0.001*0.637Pancreatitis, no. (%)70 (45.2)597 (12.2)30 (32.8)*\< 0.001*0.097ARDS, no. (%)26 (16.8)225 (4.6)6 (9.8)*\< 0.001*0.196Surgical operation, no. (%)120 (77.4)3024 (61.8)44 (72.1)*\< 0.001*0.413Intravascular catheters, no. (%)140 (90.3)2962 (60.6)61 (100.0)*\< 0.0010.012*Organ biopsy, no. (%)31 (3.7)812 (16.6)17 (27.9)0.2640.210MV, no. (%)141 (91.0)4386 (89.7)56 (91.8)0.6020.845UC, no. (%)148 (95.5)4690 (95.9)57 (93.4)0.1520.539MDRO, no. (%)67 (43.2)1660 (33.9)41 (67.2)*0.0170.002*Sepsis, no. (%)38 (24.5)332 (6.8)11 (18.0)*\< 0.001*0.306Pneumonia, no. (%)108 (69.7)2648 (54.1)45 (73.8)*\< 0.001*0.551IAI, no. (%)87 (56.1)371 (7.6)7 (11.5)*\< 0.001\< 0.001*HAIs other than NBSIs, pneumonia and IAI, no. (%)17 (11.0)161 (3.3)5 (8.2)*\< 0.001*0.544Days prior to NBSI date from ICU admission, median (IQR)13.0 (8.0--25.0)NA19.0 (12.5--30.0)NA*0.031*Outcomes LOS in ICU after NBSI date (days), median (IQR)15.0 (8.0--27.0)NA16.0 (6.0--30.0)NA0.876 LOS in hospital after NBSI date (days), median (IQR)18.0 (8.0--37.0)NA19.0 (9.5--36.5)NA0.729 LOS in ICU (days), median (IQR)32.0 (18.0--55.0)10.0 (5.0--18.0)34.0 (20.0--59.5)*\< 0.001*0.308 LOS in hospital (days), median (IQR)42.0 (24.0--68.0)21.0 (13.0--33.0)39.0 (26.0--77.5)*\< 0.001*0.533 Hospitalization costs (CNY), median (IQR)305,074 (196,575--452,309)97,591 (57,306--190,754)35,9646 (229,092--549,737)*\< 0.001*0.103 Deaths in ICU (mortality)39 (25.2)637 (13.0)20 (32.8)*\< 0.001*0.258 Predicted deaths in ICU (predicted mortality)90 (58.1)1343 (27.5)35 (57.4)*\< 0.001*0.927Predicted deaths in ICU included deaths in ICU and patients discharged from ICU against medical advice because of critical conditions and the desire to pass away at home*N-CLABSI*, non-central line-associated bloodstream infection; *SD*, standard deviation; *APACHE*, Acute Physiology and Chronic Health Evaluation; *ICU*, intensive care unit; *ARDS*, acute respiratory distress syndrome; *MV*, mechanical ventilation; *UC*, urinary catheter; *MDRO*, multidrug-resistant organism; *IAI*, intraabdominal infection; *HAI*, healthcare-associated infection; *NBSI*, nosocomial bloodstream infection; *IQR*, interquartile range; *CNY*, China Yuan; *LOS*, length of stay\*Group B included group B-sub^†^*p* values \< 0.05 are shown in italics

Impacts of N-CLABSI on the outcomes {#Sec13}
-----------------------------------

Three PS models (matching ratio 1:4, calipers value 0.02) were developed to control the confounders in the cohorts (one for logarithmic value of LOS in ICU and logarithmic value of LOS in hospital, one for logarithmic value of hospitalization costs, and another for death in ICU and predicted death in ICU). In all the three matched cohorts, the standardized differences were 0.1 or less for all baseline characteristics, demonstrating only minor differences between both the two groups (more details were shown in additional files (see Additional files [1](#MOESM1){ref-type="media"}, [2](#MOESM2){ref-type="media"}, and [3](#MOESM3){ref-type="media"})). As shown in Table [2](#Tab2){ref-type="table"}, patients with N-CLABSI did have prolonged LOS in ICU (median 15.0 days, *p* \<  0.001) and LOS in hospital (median 13.0 days, *p* \<  0.001), increased hospitalization costs (median, 186,757-yuan, equivalent to USD 27,668, *p* \<  0.001), and excess mortality in ICU (8.8%, *p* = 0.013) and predicted mortality in ICU (22.7%, *p* \<  0.001), compared with those without N-CLABSI. According to the results of the multivariate regression analysis in the PS-matched cohorts shown in Table [3](#Tab3){ref-type="table"}, N-CLABSI was an independent risk factor for each of the outcomes respectively (the adjusting factors for the PS-matched cohorts were shown in an additional file (see Additional file [4](#MOESM4){ref-type="media"})).Table 2Excess outcomes of N-CLABSI after PS matchingOutcomesMatching ratioWith N-CLABSIWithout N-CLABSIExcess values*p* value^\*^LOS in ICU (days), median (IQR)155:51832.0 (18.0--55.0)17.0 (9.0--31.0)15.0*\<  0.001*LOS in hospital (days), median (IQR)155:51842.0 (24.0--68.0)29.0 (16.0--48.0)13.0*\<  0.001*Hospitalization costs (CNY), median (IQR)155:525305,074 (196,575--452,309)118,317 (68,819--220,763)186,757*\<  0.001*Deaths in ICU (mortality)153:48738 (24.8%)78 (16.0%)8.8%*0.013*Predicted deaths in ICU (predicted mortality)153:48789 (58.2%)173 (35.5%)22.7%*\<  0.001*Predicted deaths in ICU included deaths in ICU and patients discharged from ICU against medical advice because of critical conditions and the desire to pass away at home*N-CLABSI*, non-central line-associated bloodstream infection; *PS*, propensity score; *LOS*, length of stay; *ICU*, intensive care unit; *IQR*, interquartile range; *CNY*, China Yuan\**p* values \< 0.05 are shown in italicsTable 3Relationships between N-CLABSI and each of the outcomes from multivariate analysis in the PS-matched cohortsOutcomesAdjusted *β*^\*^ or OR^†^95% CI*p* value^‡^Logarithmic value of LOS in ICU*β* = 0.2170.156--0.277*\< 0.001*Logarithmic value of LOS in hospital*β* = 0.1370.076--0.197*\< 0.001*Logarithmic value of hospitalization costs*β* = 0.2130.152--0.275*\< 0.001*Death in ICUOR = 2.1751.294--3.656*0.003*Predicted death in ICUOR = 2.9601.850--4.737*0.001*Predicted death in ICU included death in ICU and discharging from ICU against medical advice because of critical conditions and the desire to pass away at home*N-CLABSI*, non-central line-associated bloodstream infection; *PS*, propensity score; *β*, unstandardized coefficients of multiple linear regression model; *OR*, odds ratio; *CI*, confidence interval; *LOS*, length of stay; *ICU*, intensive care unit\*Continuous outcomes were analyzed by multiple linear regression models^†^Categorical outcomes were analyzed by logistic regression models^‡^*p* values \< 0.05 are shown in italics

Risk factors for N-CLABSI in ICU patients {#Sec14}
-----------------------------------------

As shown in Table [4](#Tab4){ref-type="table"}, the variables with *p* \<  0.1 in the univariate logistic regression models and those that were considered clinically relevant were selected into the multivariate logistic regression model for N-CLABSI. There was no multicollinearity within the variables in the final model. Patients with gastrointestinal bleeding (aOR 2.30, 95% CI 1.38--3.82, *p* = 0.001), trauma (aOR 2.52, 95% CI 1.57--4.04, *p* \<  0.001), pancreatitis (aOR 3.45, 95% CI 2.24--5.30, *p* \<  0.001), surgical operation (aOR 1.82, 95% CI 1.19--2.78, *p* = 0.006), intravascular catheters (aOR 2.93, 95% CI 1.65--5.22, *p* \<  0.001), sepsis (aOR 1.69, 95% CI 1.09--2.63, *p* = 0.02), pneumonia (aOR 1.53, 95% CI 1.03--2.28, *p* = 0.038), IAI (aOR 8.37, 95% CI 5.63--12.44, *p* \<  0.001), or HAIs other than NBSI, pneumonia, and IAI (aOR 3.89, 95% CI 2.09--7.24, *p* \<  0.001) were at higher risk for developing N-CLABSI in ICU patients.Table 4Risk factors for N-CLABSI in ICU patients (logistic regression)Variables\*Univariate analysisMultivariate analysisOR (95% CI)*p* value^†^Adjusted OR (95% CI)*p* value^‡^*Age (years)0.988 (0.980--0.997)0.012*1.004 (0.993--1.016)0.431Sex (male)1.322 (0.930--1.880)0.120*APACHE II score on ICU admission1.032 (1.010--1.050)0.002*1.010 (0.986--1.034)0.411Chronic underlying diseases1.033 (0.731--1.460)0.853Disorder of consciousness1.443 (0.903--2.309)0.125*Gastrointestinal bleeding2.189 (1.409--3.399)\< 0.0012.295 (1.377--3.824)0.001Trauma*1.390 (0.926--2.087)0.112*2.521 (1.573--4.040)\< 0.001*Immunological diseases0.706 (0.430--1.160)0.171Organ transplantation0.871 (0.507--1.494)0.615*Multiple organ failure2.169 (1.562--3.011)\< 0.001*1.093 (0.734--1.627)0.663*Shock2.708 (1.959--3.743)\< 0.001*1.005 (0.683--1.479)0.979*Pancreatitis5.923 (4.268--8.220)\< 0.0013.445 (2.239--5.300)\< 0.001ARDS4.180 (2.686--6.503)\< 0.001*1.673 (0.982--2.850)0.058*Surgical operation2.117 (1.446--3.098)\< 0.0011.815 (1.186--2.776)0.006Intravascular catheters6.078 (3.558--10.384)\< 0.0012.934 (1.649--5.221)\< 0.001*Organ biopsy1.256 (0.841--1.875)0.265MV1.160 (0.664--2.024)0.602UC0.621 (0.322--1.198)0.155*MDRO positive1.481 (1.072--2.046)0.017*0.732 (0.500--1.069)0.107*Sepsis4.460 (3.042--6.538)\< 0.0011.693 (1.088--2.633)0.020Pneumonia1.946 (1.376--2.754)\< 0.0011.528 (1.025--2.277)0.038IAI15.185 (10.873--21.206)\< 0.0018.369 (5.630--12.440)\< 0.001HAIs other than NBSI, pneumonia and IAI3.619 (2.135--6.135)\< 0.0013.888 (2.087--7.244)\< 0.001BSI*, bloodstream infection; *N-CLABSI*, non-central line-associated bloodstream infection; *ICU*, intensive care unit; *OR*, odds ratio; *APACHE*, Acute Physiology and Chronic Health Evaluation; *ARDS*, acute respiratory distress syndrome; *MV*, mechanical ventilation; *UC*, urinary catheter; *MDRO*, multidrug-resistant organism; *IAI*, intraabdominal infection; *HAI*, healthcare-associated infection\*The variables selected into the multivariate logistic regression model are shown in italics^†^Variables were analyzed by univariate logistic regression models. Parameters with *p* \< 0.1 are shown in italics^‡^Variables were analyzed by a multiple logistic regression model. Parameters with statistical significance (*p* \< 0.05) are shown in italics

Discussion {#Sec15}
==========

To our knowledge, this is the first time to identify the clinical impacts and risk factors for N-CLABSI in ICU patients. This study has several notable findings including (1) most of the NBSIs were N-CLABSIs in our ICU; (2) N-CLABSI was associated with poor outcomes, which include prolonged LOS in ICU and in hospital and increased hospitalization costs and all-cause mortality in ICU; (3) N-CLABSI had similar clinical impacts with CLABSI; and (4) the risk factors for N-CLABSI in this study provide possibilities to prevent N-CLABSI.

There are very few studies that reported the incidence of N-CLABSIs in NBSIs and in ICU patients directly. The proportion of N-CLABSIs could be calculated in the studies focusing on CLABSIs. The high proportion (71.8%) of N-CLABSIs in NBSIs of our study is consistent with that in the study of Laura et al. (78.0% in 2009, not shown in the study directly) \[[@CR11]\] while is much higher than 37.6% (50/133) in the study of Jinhong \[[@CR12]\] and 36.0% (44/122) in the study of Christopher et al. \[[@CR13]\]. Furthermore, the high incidence of N-CLABSIs in this study (2.3 cases per 100 ICU admissions) approximates to the total incidence of NBSIs (2.67 cases per 100 ICU admissions) in the previous study \[[@CR1]\].

Previous studies have identified that both NBSIs (as a whole) and CLABSIs were associated with poor clinical outcomes, including LOS in hospital, healthcare costs, and mortality. The prolonged LOS in ICU of CLABSIs varied from 10 to 20 days \[[@CR1], [@CR14]--[@CR17]\], excess costs of CLABSIs from \$3700 to \$39,000 \[[@CR14], [@CR18]--[@CR21]\], and the increased mortality of CLABSIs from 4 to 37% \[[@CR1], [@CR16], [@CR22], [@CR23]\]. These ranges contained the excess outcomes of N-CLABSIs in this study. However, few studies have estimated the difference in the clinical outcomes between N-CLABSIs and CLABSIs. Our study showed that N-CLABSIs had similar poor outcomes with CLABSIs. N-CLABSI was indeed a significant independent risk factor for each of the outcomes of ICU patients according to this study. Therefore, N-CLABSI should be paid more attention to than previous, especially in ICU patients.

Most previous studies focus on CLABSI with a probable reason that CLABSI has better preventability. However, the preventability of N-CLABSI is still uncertain. The risk factors for N-CLABSI in this study were significantly different from those for CLABSI \[[@CR24]--[@CR28]\]. These factors provide possibilities to prevent N-CLABSIs. Measures that could prevent pathogens from entering the bloodstream directly from the wounds or could control or prevent the infectious factors could be possible prevention strategies for N-CLABSI. For example, timely hemostasis for gastrointestinal bleeding; aseptic techniques for wound management, operation, and intravascular catheters; treating the primary infections; and preventing HAIs could be effective for preventing N-CLABSI in ICU patients. IAI (including ICU-acquired IAI) with aOR 8.37 and HAIs other than BSI, pneumonia, and IAI with aOR 3.89 were the strongest two independent risk factors for N-CLABSI. This suggests more necessity to prevent HAIs.

We are aware of the several limitations of this study. First, the relative frequency of N-CLABSIs that could be prevented was not evaluated in this study because it was difficult to identify the cause of a primary BSI and how many secondary BSIs could be prevented after primary site infections. Second, we just evaluated the medical data in one of the eight different types of ICUs of our hospital---a single-center design. The generalizability of our findings could be limited by the type of this ICU (a general ICU always admits critically ill patients) and the high prevalence of NBSIs in this unit.

Conclusions {#Sec16}
===========

In conclusion, N-CLABSI had an increased high proportion in NBSIs and high prevalence in ICU patients. N-CLABSI was associated with poor clinical outcomes, which included LOS in ICU and in hospital, hospitalization costs, and all-cause mortality in ICU, like CLABSI. Gastrointestinal bleeding, trauma, pancreatitis, surgical operation, intravascular catheters, sepsis, pneumonia, IAI, and HAIs other than NBSI, pneumonia, and IAI were risk factors for developing N-CLABSI in ICU patients, which provided some possible measures for preventing N-CLABSI, such as aseptic techniques, treating the primary infections, and preventing other HAIs.
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================

 {#Sec17}
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:   Odds ratio

PS

:   Propensity score

SD

:   Standard deviation

UC

:   Urinary catheter
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